However, flow cytometric analysis of splenocytes and tumor-infiltrating immune cells suggests that the effect of ASPH inhibition is unlikely to be driven by increased T-cell proliferation or tumor infiltration because T-cell proportions in spleens and tumors were rather lower with the combined therapy DNAvac+ASPHi compared to DNA vaccination alone. This evidence concerns the gene ASPH and neoplasm.